FBLG

Healthcare Biotechnology

FibroBiologics, Inc.

$1.18

-0.06 -4.84% today

Price History

Not enough data

Key Stats

Market Cap

8.21M

Avg Volume

198,495

EPS

-$5.01

52W High

$11.40

52W Low

$0.62

Div. Yield

0.0%

Analyst Ratings

Hold

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-0.36

P/B Ratio

1.55

EV/EBITDA

-0.38

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(660.1%)

Return on Assets

(95.8%)

Liquidity & Leverage

Current Ratio

2.64

Quick Ratio

1.59

Debt / Equity

0.32

Total Cash

3.52M

Total Debt

1.46M

About

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

fibrobiologics.com